Updated Aug. 11, 2025
FDA announces end of IV saline shortage
FDA Commissioner Dr. Marty Makary announced on Aug. 8 the official end of the nationwide shortage of sodium chloride 0.9 percent injection products, commonly known as IV saline. As a result, IV saline will be removed from the FDA’s Drug Shortage Database. Hospitals and clinics are encouraged to prioritize FDA-approved products when available. In a press release, Dr. Makary credited collaboration between the FDA, the Administration for Strategic Preparedness and Response, and industry partners with resolving the shortage. Together, they expanded manufacturing capacity, restoring stability to the supply chain. The FDA also supported temporary imports and expedited regulatory reviews to boost availability. While some IV fluids remain in short supply, the FDA continues working closely with manufacturers and will continue to monitor the supply to help ensure necessary patient access to these medicines.
